COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?Research article Published on 2021-06-012022-10-05 Journal: Multiple sclerosis and related disorders [Category] SARS, 유전자 메커니즘, [키워드] Analysis association attack bystander control group COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 severity Hospitalized incidence incidence rate independent likelihood lymphopenia memory cell Multiple multiple sclerosis no significant difference not different objective Patient patients with COVID-19 patients without COVID-19 Post-infection Relapse Relapsing-Remitting Multiple Sclerosis Result retrospective cohort study risk SARS-CoV-2 sclerosis was recorded [DOI] 10.1016/j.msard.2021.102915 [Article Type] Research article
Early Aggressive Treatment Approaches for Multiple Sclerosisarticle Published on 2021-05-152024-09-04 Journal: Current Treatment Options in Neurology [Category] 대상포진, [키워드] clinical trials Disease-modifying therapy High-efficacy therapies multiple sclerosis Relapsing-Remitting Multiple Sclerosis [DOI] 10.1007/s11940-021-00677-1 PMC 바로가기 [Article Type] article
Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review항종양 및 항바이러스 잠재력을 갖지만 약물 유발 간 손상을 갖는 레플루노마이드 면역조절제: 포괄적인 검토Review Published on 2021-04-012022-09-11 Journal: International immunopharmacology [Category] SARS, 임상, 치료제, [키워드] affected Anti-inflammatory Antineoplastic Antiviral antiviral activity approved Arthritis Autoimmune benefit Bilirubin Biomarkers catalytic Cell cell growth cellular Combination Compound COVID-19 Cytokines de novo synthesis DHODH drug drug-induced Drug-induced liver injury enzyme event growth hepatic impairment hepatic injury Immunoglobulin immunological immunomodulator Immunosuppression inhibit inhibitors joint destruction leflunomide Leflunomide. liver liver enzyme liver enzymes Liver injury membrane mitochondrial nucleotide nucleotides off-label outcome Pathogenesis pathophysiology Patient Perspective pharmacological precautions proliferation Protective Protein pyrimidine reducing Regulatory Relapsing-Remitting Multiple Sclerosis reported required responsible Rheumatoid safety profile SARS CoV SARS CoV-2 serum Treatment Trial tyrosine with COVID-19 [DOI] 10.1016/j.intimp.2021.107398 PMC 바로가기 [Article Type] Review
COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on OcrelizumabCase Report Published on 2021-03-042022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] B cell B-cell COVID-19 COVID-19 mRNA vaccine COVID-19 pandemic COVID-19 vaccine depleting Efficacy failure Humoral immunity immunosuppressive therapies IMPROVE Infection management Multiple multiple sclerosis Ocrelizumab offer Patient patients receiving Relapsing-Remitting Multiple Sclerosis sclerosis therapy vaccination Vaccine vaccine response [DOI] 10.3390/vaccines9030219 PMC 바로가기 [Article Type] Case Report
Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreakArticle Published on 2020-10-012023-07-06 Journal: Multiple sclerosis and related disorders [Category] SARS, [키워드] Anxiety COVID-19 Depression Quality of life Relapsing-Remitting Multiple Sclerosis [DOI] 10.1016/j.msard.2020.102407 PMC 바로가기
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension studyOriginal Research Papers Published on 2018-10-052024-09-04 Journal: Multiple Sclerosis Journal [Category] 대상포진, [키워드] Alemtuzumab Disease-modifying therapy Infection Relapsing-Remitting Multiple Sclerosis Safety [DOI] 10.1177/1352458518796675 PMC 바로가기 [Article Type] Original Research Papers
Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosisReview Published on 2017-07-282024-09-04 Journal: Drug Design, Development and Therapy [Category] 대상포진, [키워드] comparison Efficacy oral agents Relapsing-Remitting Multiple Sclerosis Safety [DOI] 10.2147/DDDT.S137572 PMC 바로가기 [Article Type] Review
Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM StudyOriginal Research Published on 2015-07-142024-09-04 Journal: Advances in therapy [Category] 대상포진, [키워드] fingolimod FIRST LATAM First-dose observations Latin American Relapsing-Remitting Multiple Sclerosis Safety [DOI] 10.1007/s12325-015-0224-2 PMC 바로가기 [Article Type] Original Research